Sage Therapeutics, Inc. functions as a biopharmaceutical enterprise, dedicated to the discovery, development, and market introduction of therapeutic agents aimed at central nervous system (CNS) conditions. Its primary medication is ZULRESSO, an intravenous form of brexanolone, prescribed for the treatment of postpartum depression (PPD) in adult patients. The company's advanced pipeline includes zuranolone, a neuroactive steroid, which is presently undergoing Phase III clinical trials for several disorders, such as PPD, major depressive disorders, treatment-resistant depression, generalized anxiety disorders, and bipolar depression. Another investigational compound, SAGE-324, is in Phase II studies for essential tremors, having already completed Phase I trials for epilepsy and Parkinson's disease. Furthermore, SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, has concluded its Phase I clinical assessments for a range of indications including depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. To enhance its global reach and innovative efforts, Sage Therapeutics has established significant collaborations. This comprises a strategic partnership with Shionogi & Co., Ltd. for the advancement and commercialization of zuranolone in Japan, Taiwan, and South Korea. Additionally, the company holds a collaboration and licensing agreement with Biogen MA Inc. for the joint development and marketing of its SAGE-217 and SAGE-324 products. Incorporated in 2010 and based in Cambridge, Massachusetts, the firm was initially known as Sterogen Biopharma, Inc., before officially changing its name to Sage Therapeutics, Inc. in September 2011.